Loading company…
Cambridge biotech developing NLRP3 inflammasome inhibitors for chronic inflammatory diseases.
NodThera Limited develops therapies for chronic inflammatory diseases based on its NLRP3 inflammasome inhibitors, with pipeline assets targeting conditions such as obesity and neurodegenerative diseases. Founded in 2016 and headquartered in Cambridge, UK, the company completed a Series B round of GBP 32.40 million led by Novo Holdings on June 2, 2020, at a valuation of GBP 109.075 million. CEO Alan Watt leads the company, which reported 2021 revenue of GBP 0.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in